These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25732500)

  • 1. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access.
    Rutkow L; Turner L; Lucas E; Hwang C; Alexander GC
    Health Aff (Millwood); 2015 Mar; 34(3):484-92. PubMed ID: 25732500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Care Physicians' Knowledge and Attitudes Regarding Prescription Opioid Abuse and Diversion.
    Hwang CS; Turner LW; Kruszewski SP; Kolodny A; Alexander GC
    Clin J Pain; 2016 Apr; 32(4):279-84. PubMed ID: 26102320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees.
    Wen H; Schackman BR; Aden B; Bao Y
    Health Aff (Millwood); 2017 Apr; 36(4):733-741. PubMed ID: 28373340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physician perspectives on a pilot prescription monitoring program.
    Barrett K; Watson A
    J Pain Palliat Care Pharmacother; 2005; 19(3):5-13. PubMed ID: 16219606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.
    Patrick SW; Fry CE; Jones TF; Buntin MB
    Health Aff (Millwood); 2016 Jul; 35(7):1324-32. PubMed ID: 27335101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
    Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
    J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators.
    Katz N; Houle B; Fernandez KC; Kreiner P; Thomas CP; Kim M; Carrow GM; Audet A; Brushwood D
    Pain Med; 2008; 9(5):587-94. PubMed ID: 18565002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
    Sneed RC; May WL; Stencel C
    Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP).
    Blum CJ; Nelson LS; Hoffman RS
    J Subst Abuse Treat; 2016 Nov; 70():35-43. PubMed ID: 27692186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription Drug Monitoring Programs: Relationships Among Program Awareness, Use, and State Mandates.
    Williams KS; Magalotti S; Schrouder K; Knox M; Feldman L; Ujwal D; Lynch D
    J Pain Palliat Care Pharmacother; 2018; 32(2-3):129-133. PubMed ID: 30198819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of the nonmedical use of prescription opioid analgesics.
    Gilson AM; Kreis PG
    Pain Med; 2009 Jul; 10 Suppl 2():S89-100. PubMed ID: 19691688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool.
    Gershman JA; Gershman JA; Fass AD; Popovici I
    Pain Med; 2014 Dec; 15(12):2013-9. PubMed ID: 24931295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of state prescription drug monitoring programs: a state-by-state survey.
    Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug monitoring programs and death rates from drug overdose.
    Paulozzi LJ; Kilbourne EM; Desai HA
    Pain Med; 2011 May; 12(5):747-54. PubMed ID: 21332934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic noncancer pain management in primary care: family medicine physicians' risk assessment of opioid misuse.
    Kavukcu E; Akdeniz M; Avci HH; Altuğ M; Öner M
    Postgrad Med; 2015 Jan; 127(1):22-6. PubMed ID: 25539797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-medical use and abuse of commonly prescribed medications.
    Riggs P
    Curr Med Res Opin; 2008 Mar; 24(3):869-77. PubMed ID: 18267053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National drug control policy and prescription drug abuse: facts and fallacies.
    Manchikanti L
    Pain Physician; 2007 May; 10(3):399-424. PubMed ID: 17525776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs?
    Smith RJ; Kilaru AS; Perrone J; Paciotti B; Barg FK; Gadsden SM; Meisel ZF
    Pain Med; 2015 Jun; 16(6):1122-31. PubMed ID: 25688454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discussing Opioid Risks With Patients to Reduce Misuse and Abuse: Evidence From 2 Surveys.
    Hero JO; McMurtry C; Benson J; Blendon R
    Ann Fam Med; 2016 Nov; 14(6):575-577. PubMed ID: 28376444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.